Adamis Pharmaceuticals Corporation (ADMP)
ADMP Price and Sentiment
ADMP Latest news
If you're making a penny stocks watchlist right now, check these three small-caps out The post Top Penny Stocks to Watch Making Big Moves Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Adamis Pharmaceuticals (ADMP) stock is getting a major boost on Monday thanks to a response from the U.S. Food and Drug Administration. The post ADMP Stock: The FDA News That Has Penny Stock Adamis Pharmaceuticals Rocketing Today appeared first on InvestorPlace.
A jump in penny stock prices has retail traders cashing out on big gains. The post Penny Stocks To Watch Today As Buying Drives ADMP, IO, LPCN & Others appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Adamis Pharmaceuticals stock rockets on heavy volume after opioid overdose treatment gets FDA approval2021-10-18 08:55
Shares of Adamis Pharmaceuticals Corp. ADMP, +2.73% soared 20.4% on massive volume toward an eight-month high in premarket trading Monday, after the biopharmaceutical company said Zimhi, it's high-dose naloxone injection for the treatment for opioid overdose, has been approved by the Food and Drug Administration. Trading volume spiked to 32.8 million shares, enough to make the stock the most actively traded ahead of the open, and compared with the full-day average of about 2.0 million shares.
The stock price of Adamis Pharmaceuticals Corp (NASDAQ: ADMP) increased by over 35% pre-market today. This is why it happened.
New High-Dose Naloxone Product for the Treatment of Opioid Overdose New High-Dose Naloxone Product for the Treatment of Opioid Overdose
Appointment of New Director with Significant Experience in Drug Development, Licensing and Commercialization Appointment of New Director with Significant Experience in Drug Development, Licensing and Commercialization
Adamis Pharmaceuticals: TEMPOL's Near-Term And Long-Term Upside Improves As Variants Sidestep Vaccines2021-09-03 14:51
Despite vaccines having some degree of efficacy against SARS-CoV-2, vaccinated patients around the world are still getting infected and capitulating to COVID-19. Antiviral drugs could be the answer.
Adamis (ADMP) starts dosing patients in phase II/III study to evaluate its oral investigational antiviral for the treatment of COVID-19.
Adamis Pharmaceuticals Doses First Patients in Phase 2/3 Clinical Trial for Tempol in the Treatment of COVID-192021-09-02 07:30
SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the initiation of patient dosing in the Phase 2/3 clinical trial for Tempol, an oral antiviral product candidate, in adult patients with confirmed COVID-19 infection. In preclinical studies, Tempol has been shown to have antiviral, anti-inflammatory and antioxidant activity. The trial is designed to enroll 248 patients.